PPITherapie
PPITherapie, also known as proton‑pump‑inhibitor therapy, is a pharmacological treatment that reduces gastric acid secretion by inhibiting the hydrogen‑potassium ATPase enzyme (the proton pump) located in the parietal cells of the stomach lining. The class of drugs includes omeprazole, esomeprazole, lansoprazole, pantoprazole and rabeprazole, among others. By raising gastric pH, PPITherapie promotes healing of acid‑related mucosal damage and alleviates symptoms associated with hypersecretory conditions.
The principal indications for PPITherapie are gastro‑oesophageal reflux disease (GERD), peptic ulcer disease, Helicobacter pylori eradication
The therapeutic effect is achieved through irreversible binding of the drug to the luminal side of the
Common adverse effects are generally mild and include headache, diarrhoea, constipation, nausea and abdominal pain. Longer‑term
Research continues to evaluate the benefits of intermittent dosing, de‑prescribing strategies, and the role of PPITherapie